As a leading global research and development-based pharmaceutical company, Eisai conducts drug discovery and research activities by applying cutting-edge knowledge and technologies to various disease areas. In order to efficiently accomplish social good based on the hhc eco, we believe that the objective of our research and development (R&D) activities is to relieve anxiety over health that patients and the people in the daily living domain experience every day, to reduce health disparities and to improve the quality of life and well-being of patients, through providing innovative medicines and preventive solutions more quickly to meet healthcare needs that patient explicitly and implicitly have.
In addition to the areas of neurology and oncology, we consider that drug discovery for diseases, for example neglected tropical diseases (NTDs) for which there is a high need in developing countries but which have not been targeted by pharmaceutical companies in developed countries, and for malaria and tuberculosis where the need for new drug discovery remains high, are important R&D activities to improve access to medicines.
To achieve social good through drug discovery for those diseases with efficiency, it is necessary to develop the tools and techniques for research on those diseases, as well as to have experience in conducting clinical trials in disease-endemic regions and to establish networking with clinical sites. Many of our projects on NTDs, malaria, and other diseases are driven by partnerships, which are referred to as Product Development Partnerships, between academic researchers and international non-profit research institutions that have the capacity to conduct high quality clinical trials in the front line and a global network of research. We believe that by maximizing each strength in such a partnership, as well as by utilizing public-private partnership funds and external funding to support global health, we can proceed with R&D activities efficiently and rapidly while sharing the risks associated with development and the essential resource.
Eisai will continue its R&D activities in order to deliver our products to more patients and people at the risk of infection around the world.